Hanmi Science signed a research agreement for public health with Policlinico Universitario Agostistino Gemelli, a hospital of Università Cattolica del Sacro Cuore in Italy, on Oct. 5.
Under the agreement, the Korean pharmaceutical company and Italian university hospital will conduct research and development in such areas as low birthrate, newborn health, systematic public prenatal care and postpartum care, which are common social issues in Korea and Italy
The department of nursing at the Italian university plans to teach Korea’s post-maternal management system and practice health promotion of women and babies. They also plan to establish the “Woman Center” to teach the new subjects in Italy. The two sides also agreed on case and model studies on public postpartum care in their countries.
“The U.N. Declaration on the Rights of the Child states that pre- and post-maternal mothers and children have the right to adequate social protection and care,” said Im Jong-yun 임종윤, CEO of Hanmi Science. “This agreement is the practice of the spirit of the United Nations and an academic effort for attaining harmony between the East and the West seeking public welfare.”
Hanmi Science 한미사이언스 has been actively pursuing post-maternal care, infant care and powdered formula business in Korea and China. Following the opening of the premium postpartum care center "Centre of Mam" in Beijing in August, they are ready to open "Woman Center" in Rome and Los Angeles in 2018.
In Italy, the company operates a local corporation called COREE S.r.l, which promotes infant and toddler products and dairy products. Since 2015, researchers at Università Cattolica del Sacro Cuore and Policlinico Universitario Agostistino Gemelli have been working on developing a powdered formula and liquid raw milk.
<© Korea Biomedical Review, All rights reserved.>